Posted by Michael Wonder on 08 Nov 2017
GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease
7 November 2017 - GlaxoSmithKline today announced the submission of a supplemental biologics license application to the United States FDA, seeking approval of mepolizumab, an interleukin-5 antagonist, as an add-on to maintenance treatment for patients who have chronic obstructive pulmonary disease with an eosinophilic phenotype.
The submission includes phase III data from the previously reported METREX and METREO studies.
